基本信息:
- 专利标题： 신규한 ｍｉＲＮＡ ｈｃ－ｓｍＲ－Ｓ２－５ 및 이의 용도
- 专利标题（英）：NOVEL miRNA hc-smR-S2-5 AND USE THEREOF
- 专利标题（中）：新型miRNA hc-smR-S2-5及其用途
- 申请号：KR1020120017615 申请日：2012-02-21
- 公开(公告)号：KR101308924B1 公开(公告)日：2013-09-23
- 发明人： 김진경 , 정형민 , 유중기 , 이지민
- 申请人： 차의과학대학교 산학협력단
- 申请人地址： 경기도 포천시 해룡로 ***, 차의과학대학교내 (동교동)
- 专利权人： 차의과학대학교 산학협력단
- 当前专利权人： 차의과학대학교 산학협력단
- 当前专利权人地址： 경기도 포천시 해룡로 ***, 차의과학대학교내 (동교동)
- 代理人： 특허법인다울
- 主分类号： C12N15/113
- IPC分类号： C12N15/113 ; C12N15/85 ; A61K31/7105 ; C12Q1/68
The present invention relates to the prevention and treatment of lung cancer pharmaceutical composition containing the novel miRNA-hc smR-S2-5 and the miRNA, particularly a novel human cancer cells derived from cancer-small RNA (human cancer-small RNA, hc-smR) -S2-5 form a hairpin (stem-loop) structure, and preserves their sequence in mammals, and low expression in lung cancer cells, human mesenchymal-epithelial transition factor (mesenchymal-epithelial transition factor, and directly inhibit the c-Met) at the mRNA and protein levels, over-expression of the hc-smR-S2-5 in lung cancer cells is confirmed to reduce the proliferation and migration of cells through the cell cycle and reducing c-Met-related protein by, for hc-smR-S2-5 it can be seen that could be useful in cancer treatment and prevention.
公开/授权文献:
- KR1020130096347A 신규한 ｍｉＲＮＡ ｈｃ－ｓｍＲ－Ｓ２－５ 및 이의 용도 公开/授权日：2013-08-30